Newamsterdam Pharma Company N v (NAMS) - News Archive

Showing 4 of 24 results.

NewAmsterdam Pharma’s Combination Therapy Shows Promise in Reducing Cardiovascular Risks Associated with Elevated LDL Cholesterol

NewAmsterdam Pharma to Present Promising Findings at the 2024 American College of Cardiology Congress: Combining Obicetrapib and Ezetimibe Shows Potential in Reducing Cardiovascular Risks Associated with Elevated LDL Ch...

Mar 25, 2024 Product Service News

NewAmsterdam Pharma Company N.V. Raises $175.3 Million in Successful Public Offering to Advance Groundbreaking Cardiovascular Treatment Innovation

New Amsterdam Pharma Company N.V. (NAMS) Announces Pricing of Public Offering, Benefitting Shareholders and Advancing Cardiovascular Disease Treatment InnovationNAARDEN, the Netherlands and MIAMI, Feb. 13, 2024 - NewAms...

Feb 14, 2024 Stock Market Announcement

NewAmsterdam Pharma Announces Public Offering to Support Innovative Cardiovascular Disease Therapies

NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded WarrantsNAARDEN, The Netherlands and MIAMI, Feb. 13, 2024 - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; NewAmsterdam or...

Feb 13, 2024 Financing Agreement

New Amsterdam Pharma Breakthrough: Announcing 2024 Strategic Goals & Upcoming Phase 3 Clinical Trials

New Amsterdam Pharma, a trailblazer in the world of healthcare solutions and pharmaceutical exploration, has recently announced its strategic priorities for the year 2024. This crucial announcement plots down the biopha...

Jan 4, 2024 Clinical Study